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Abstract
Neoantigens are newly formed peptides created from somatic mutations that are capable of inducing tumor-
specific T cell recognition. Recently, researchers and clinicians have leveraged next generation sequencing
technologies to identify neoantigens and to create personalized immunotherapies for cancer treatment. To create a
personalized cancer vaccine, neoantigens must be computationally predicted from matched tumor–normal
sequencing data, and then ranked according to their predicted capability in stimulating a T cell response. This
candidate neoantigen prediction process involves multiple steps, including somatic mutation identification, HLA
typing, peptide processing, and peptide-MHC binding prediction. The general workflow has been utilized for many
preclinical and clinical trials, but there is no current consensus approach and few established best practices. In this
article, we review recent discoveries, summarize the available computational tools, and provide analysis
considerations for each step, including neoantigen prediction, prioritization, delivery, and validation methods. In
addition to reviewing the current state of neoantigen analysis, we provide practical guidance, specific
recommendations, and extensive discussion of critical concepts and points of confusion in the practice of
neoantigen characterization for clinical use. Finally, we outline necessary areas of development, including the need
to improve HLA class II typing accuracy, to expand software support for diverse neoantigen sources, and to
incorporate clinical response data to improve neoantigen prediction algorithms. The ultimate goal of neoantigen
characterization workflows is to create personalized vaccines that improve patient outcomes in diverse cancer
types.
Background
The adaptive immune system has inherent antitumor
properties that are capable of inducing tumor-specific
cell death [1, 2]. CD8+ and CD4+ T cells, two immune
cell types that are critical to this process, recognize anti-
gens bound by class I and II major histocompatibility
complexes (MHC) on the cell surface, respectively. After
antigen recognition, T cells have the ability to signal
growth arrest and cell death to tumor cells displaying
the antigen, and also release paracrine signals to propa-
gate an antitumor response. Neoantigens are specifically
defined here as peptides derived from somatic mutations
that provide an avenue for tumor-specific immune cell rec-
ognition and that are important targets for cancer immuno-
therapies [3–5]. Studies have shown that, in addition to
tumor mutational burden (TMB), high neoantigen burden
can be a predictor of response to immune checkpoint block-
ade (ICB) therapy [6, 7]. This treatment strategy targets the
signaling pathways that suppress antitumor immune re-
sponses, allowing the activation of neoantigen-specific T
cells and promoting immune-mediated tumor cell death.
Therefore, accurate neoantigen prediction is vital for the
success of personalized vaccines and for the prioritization of
candidates underlying the mechanism of response to ICB.
These approaches have great therapeutic potential because
neoantigen-specific T cells should not be susceptible to cen-
tral tolerance.
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With the advent of next generation sequencing (NGS),
researchers can now rapidly sequence a patient’s DNA and
RNA before analyzing these sequencing data to predict
neoantigens computationally. This process requires several
steps, each involving the use of bioinformatics tools and
complex analytical pipelines (Fig. 1; Table 1). Matched
tumor–normal DNA sequencing data are processed and
analyzed to call somatic mutations of various types. Human
leukocyte antigen (HLA) haplotyping is performed to deter-
mine a patient’s HLA alleles and the corresponding MHC
complexes. Finally, RNA sequencing (RNA-seq) data are
used to quantify gene and transcript expression, and can
verify variant expression prior to neoantigen prediction.
Multiple pipelines exist to identify candidate neoantigens
that have high binding affinities to MHC class I or II. Add-
itional steps are subsequently required to prioritize them
for clinical use in personalized vaccines and to address
manufacturing and delivery issues [8, 9].
The general concept of neoantigens and their role in per-
sonalized immunotherapies have been extensively reviewed
elsewhere [10–12]. Although experimental methods exist to
assess neoantigens (e.g., mass spectrometry (MS)), the focus
of this review is a comprehensive survey of computational
approaches (tools, databases, and pipelines) for neoantigen
characterization. The ultimate goal is to discover neoepi-
topes, the part of the neoantigen that is recognized and
bound by T cells, but current workflows are largely focused
on predicting MHC-binding antigens with limited predic-
tion of recognition by T cells or therapeutic potential. We
have been particularly inspired by the use of computational
approaches in human clinical trials involving personalized
neoantigen vaccines alone or in combination with ICB. A
rapid expansion of the number and diversity of these trials
has occurred over the past few years, but there is limited
community consensus on approaches for neoantigen
characterization. Adoption of standards for the accurate
Fig. 1 Overview of the bioinformatic characterization of neoantigens. Major analysis steps in a comprehensive workflow for neoantigen
characterization are depicted in a simplified form. For each component, critical concepts and analysis considerations are indicated. Specific
exemplar bioinformatics tools for each step are indicated in italics. Starting at the top left, patient sequences are analyzed to determine human
leukocyte antigen (HLA) types and to predict the corresponding major histocompatibility complexes (MHC) for each tumor. Somatic variants of
various types, including single nucleotide variants (SNVs; blue), deletions (red), insertions (green), and fusions (pink), are detected and the
corresponding peptide sequences are analyzed with respect to their predicted expression, processing, and ability to bind the patient’s MHC
complexes. Candidates are then selected for vaccine design and additional analyses are performed to assess the T cell response. Abbreviations:
CDR3 complementarity-determining region 3, FFPE formalin-fixed paraffin-embedded, IEDB Immune Epitope Database, TCR T cell receptor
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identification of neoantigens and for the reporting of their
features will be critical for the interpretation of results from
early-stage trials and for the optimization of future trials.
This review is focused on human clinical data; nevertheless,
neoantigen characterization work involving model organ-
isms (such as mice) will be critical to advance the field, and
many of the tools and approaches described herein may be
applied to these model systems with appropriate modifica-
tions. In addition to describing emerging best practices, we
highlight the current limitations and critical areas for the
improvement of the computational approaches needed to
understand the immunogenicity of neoantigens.
Neoantigen identification
Two types of antigens that can induce an antitumor re-
sponse are tumor-specific antigens (or neoantigens) and
tumor-associated antigens (TAA). Neoantigens contain
altered amino-acid sequences that result from non-silent
somatic mutations, whereas TAAs, which may originate
from endogenous proteins or retroviruses, are selectively
expressed or overexpressed by tumor cells but may also
be expressed by non-tumor cell populations [13]. This re-
view focuses on the detection and selection of neoanti-
gens, but many analytical steps that are used can apply to
other antigen types. Considerations such as sample type
(fresh frozen, formalin-fixed paraffin-embedded (FFPE)
tissue or circulating tumor DNA (ctDNA)), tumor type
(solid or blood), biopsy site, and sequencing approach
(DNA, RNA, or targeted sequencing) can impact somatic
variant detection and interpretation, and should be taken
into account during data processing and downstream ana-
lysis [13–16]. In addition, tumors that exhibit high intratu-
moral heterogeneity can require alternative methods, such
as collecting multiple biopsies per tumor [17].
Somatic variant callers identify single nucleotide variants
(SNVs) from tumor and matched non-tumor DNA se-
quence data, such as whole genome, or more commonly,
whole exome sequencing (WES) data [18]. Three common
Table 1 Tool categories, a brief description of their roles and a list of exemplar tools
Tool categories Function and examples
Alignment DNA: Bwa-mem [161]
RNA: STAR [162], HISAT2 [163]
Sequence data QC Picard (http://broadinstitute.github.io/picard/), FastQC (https://github.com/s-andrews/FastQC), RSeQC [164], MultiQC
(https://github.com/ewels/MultiQC) (note that MultiQC supports an extensive list of additional QC tools)
Variant callers SNV/Indel: Mutect [19], Strelka [20], VarScan2 [21], SomaticSniper [22], Shimmer [165], VarDict [166], deepSNV [167],
EBCall [40]
Structural variants: Pindel [43], Manta [168], Lumpy [169]
Fusions: STAR-Fusion [48], Pizzly [47], SOAPfuse [170], JAFFA [49], ChimPipe [171], GFusion [50], INTEGRATE [51]
Variant call format (VCF)
manipulation
Vt decompose (https://github.com/atks/vt), GATK (https://github.com/broadinstitute/gatk) (e.g., SelectVariants,
CombineVariants, LeftAlignAndTrimVariants)
Variant annotation Variant Effect Predictor (VEP) (https://github.com/Ensembl/ensembl-vep) (SNV/Indel), AGFusion [172] (RNA fusions),
bam-readcount (https://github.com/genome/bam-readcount), VAtools (https://github.com/griffithlab/VAtools)
Gene or transcript abundance
estimation
StringTie [173], Kallisto [174]
HLA typing Class I: Optitype [69], Polysolver [70]
Class I and II: Athlates [70, 175], HLAreporter [176], HLAminer [176, 177], HLAscan [72, 178], HLA-VBSeq [72], PHLAT [71],
seq2HLA [73], xHLA [74]
Peptide processing Proteasome cleavage: NetChop20S [89], NetChopCterm [89], ProteaSMM [89, 90], PAProC [179] (Class I),
PepCleaveCD4 [91] (Class II)
TAP transport efficiency: [90] (no specific tool name)
MHC binding predictors Class I predictors: SMM [111], SMMPMBEC [112], Pickpocket [113], NetMHC [114], NetMHCpan [87], NetMHCcons
[180], MHCflurry [102], MHCnuggets [181], MHCSeqNet [103], EDGE [104]
Class II predictors: SMMAlign [111], NNAlign [182], ProPred [183], NetMHCII(2.3) and NetMHCIIpan(3.2) [116],
TEPITOPE [184], TEPITOPEpan [185], RANKPEP [186], MultiRTA [187], OWA-PSSM [188]
Neoantigen prioritization
pipelines
pVACtools [8], Vaxrank [9], MuPeXI [119], TIminer [120], Neoepiscope [189], TSNAD [190], EpiToolKit [123],
NeoepitopePred [122], TepiTool (IEDB) [191], ScanNeo [192], CloudNeo [193], NeoPredPipe [118]
Peptide creation and delivery pVACtools [8] (pVACvector), Vaxrank [9] (manufacturability)
TCR repertoire profiling LymAnalyzer [194], MiXCR [147], MIGEC [148], pRESTO [195], TRUST [196], TraCeR [145], VDJtools [197], VDJviz [198],
ImmunoSEQ [199], GLIPH [151]
Immune cell profiling CIBERSORT [152], TIMER [153], quanTIseq [200], immunophenogram [201], MCPcounter [202], SSGSEA [203]
This table compiles the current state of tools, databases, and other resources that are used in neoantigen pipelines. Although many of the steps that are outlined
may involve the integration of multiple tools for comparable predictions (e.g., using multiple somatic variant callers or MHC-binding-affinity predictors), this table
summarizes more options than are needed in a single workflow. For an example of the specific combination of tools, parameter settings, and order of operations
used in a real end-to-end workflow that is based on our own practices, please refer to our online tutorial for precision medicine bioinformatics (https://pmbio.org/
). TAP Transporter associated with antigen processing
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limitations to SNV calling—low frequency variant detec-
tion, distinguishing germline variants from tumor in normal
contamination, and removing sequencing artifacts—have
been addressed by the variant callers discussed below.
MuTect2 [19] and Strelka [20] have high sensitivity in de-
tecting SNVs at low allele fractions, enabling accurate sub-
clonal variant detection. VarScan2 [21] and SomaticSniper
[22] require higher allele fractions for recognizing variants
but can improve performance in cases of tumor in normal
contamination [23, 24]. MuTect2 can further exclude se-
quencing or alignment artifacts by implementing a panel-
of-normals file, containing false positives detected across
normal samples. Running multiple variant calling algo-
rithms simultaneously is recommended and can result in
higher detection accuracy. For example, Callari et al. [25]
achieved 17.1% higher sensitivity without increasing the
false-positive rate by intersecting a single variant caller’s re-
sults from multiple alignment pipelines and then combin-
ing the intersected results from two callers, MuTect2 and
Strelka, to achieve a final consensus. The list of variant cal-
lers mentioned here is not exhaustive (see Table 1 for add-
itional options) and high-quality pipelines using different
combinations are certainly possible. Regardless of the com-
bination of callers used, manual review of matched
tumor–normal samples in Integrative Genomics Viewer
(IGV) [26], with a documented standard operating pro-
cedure, is recommended to further reduce false positives
[27]. In addition to IGV, targeted sequencing approaches
such as custom capture reagents can be utilized for further
variant validation.
Recently, neoantigen vaccine trials for melanoma demon-
strated that SNV-derived neoantigens can expand T cell
populations [28] and induce disease regression [29, 30].
However, recent studies have also increased appreciation
for diverse neoantigen sources beyond simple SNVs, in-
cluding short insertions and deletions (indels) [31], fusions
[32, 33], intron retentions [34], non-coding expressed re-
gions [35], exon–exon junction epitopes [36], B cell recep-
tor (BCR) and T cell receptor (TCR) sequences for B and T
cell malignancies, respectively [37], and more [38].
Frameshift mutations resulting from insertions and dele-
tions create alternative open reading frames (ORFs) with
novel tumor-specific sequences that are completely distinct
from those that encode wild-type antigens. A pan-cancer
analysis of 19 cancer types from The Cancer Genome Atlas
demonstrated that frameshift-derived neoantigens were
present in every cancer type [31]. This mutation type also
occurs frequently in microsatellite instability high (MSI-H)
colon and other cancers and correlates with higher CD8+
T cell infiltrate in the tumors [31, 39]. For calling indels, in
addition to Strelka, EBCall [40] demonstrates the least sen-
sitivity to coverage variability [41, 42]. Pindel [43] special-
izes in calling larger indels, from 0.50–10 kilobases in
length, and structural variants. Though these are popular
indel callers, they are only a subset of the available tools
(see Table 1 for additional options).
Translocations may result in tumor-specific fusion
genes, which can alter the reading frame and provide
novel junction sequences. Researchers recently investi-
gated the presence of translocations in osteosarcoma,
characterized by high genomic instability [44], and dis-
covered multiple fusion-derived junction-spanning
neoantigens [45]. The identification of novel sequences
resulting from inter- and intrachromosomal rearrange-
ments in mesothelioma also resulted in the prediction of
multiple neoantigens for each patient [46]. Many tools
have been developed to predict fusion genes from RNA-
seq and/or whole genome sequencing (WGS) data; recent
tools include pizzly [47], STAR-fusion [48], JAFFA [49],
GFusion [50], and INTEGRATE [51] (refer to Table 1).
The main limitation of these fusion callers is the low level
of overlap between tools; they largely achieve high sensi-
tivity at the cost of low specificity. The presence of many
false positives makes accurate detection difficult, but this
can be mitigated by using multiple tools [52] and by re-
quiring predictions to be supported by multiple callers
and/or data types (e.g., WGS and RNA-seq).
In addition to mutation-derived neoantigens from
known protein-coding genes, noncoding regions have im-
munogenic potential. Noncoding transcripts can be cre-
ated from noncoding exons, introns, and untranslated
regions (UTRs), as well as from non-canonical reading
frames in the coding region [53]. Laumont et al. [35] in-
vestigated traditionally noncoding sequences using liquid
chromatography tandem-MS (LC-MS/MS) and RNA se-
quencing (RNA-seq) in leukemia and lung cancer patients
and found an abundance of antigens, both mutated and
unmutated, from noncoding regions.
Recent publications have shown that aberrant tumor-
specific splicing patterns can create neoantigens. Smart
et al. [54] found an approximately 70% increase in total
predicted neoantigens after including retained intron se-
quences along with SNVs in the prediction pipeline. Novel
junctions created by exon skipping events, or neojunc-
tions, have been shown to create neoantigens [36].
Tumor-specific splicing patterns can also cause distinct al-
ternative 3′ or 5′ splice sites, known as splice-site-creating
mutations, and these mutations are predicted to create an
average of 2.0–2.5 neoantigens per mutation [55].
In addition to the neoantigen sources discussed above,
many alternative sources can create neoantigens. For ex-
ample, V(D) J recombination and somatic hypermutation
generate immunoglobulin (Ig) variable region diversity in
B and T lymphocytes, and the resulting unique receptor
sequences can function as neoantigens in heme malignan-
cies [37, 56]. Further, researchers have demonstrated that
peptides with post translational modifications, including
phosphorylation and O-GlcNAcylation, in primary
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leukemia samples can serve as MHC-I restricted neoanti-
gens [57, 58]. Alternative translation events resulting from
non-AUG start codons and viral sequences that are associ-
ated with tumors (e.g., human papilloma virus (HPV)) are
also a source of neoantigens [59–63]. Overall, neoantigen
identification requires a sensitive, accurate, and comprehen-
sive somatic variant calling pipeline that is capable of ro-
bustly detecting all of the variant classes that are relevant for
a tumor type (Table 2).
HLA typing, expression, and mutation analysis
T cell priming depends in part on neoantigen presentation
on the surface of dendritic cells, a type of professional
antigen presenting cells (APCs). Dendritic cells engulf
extracellular proteins, process the peptides, and present
the neoantigens on MHC I or II molecules. MHC in
humans is encoded by the HLA gene complex, which is
located on chromosome 6p21.3. This locus is highly poly-
morphic, with over 12,000 established alleles and more in
discovery [64]. Because HLA genes are extensively individ-
ualized, precise HLA haplotyping is essential for accurate
neoantigen prediction. The gold standard for this process
is clinical HLA typing using sequence-specific PCR ampli-
fication [65]. More recently, NGS platforms such as Illu-
mina MiSeq and PacBio RSII have been combined with
PCR amplification to sequence the HLA locus [66]. How-
ever, clinical typing can be laborious and expensive, so a
common alternative approach is computational HLA typ-
ing using the patient’s WGS, WES, and/or RNA-seq data-
sets, which are typically created from a peripheral blood
sample, except in heme malignancies, where a skin sample
is often used (Table 2).
HLA class I typing algorithms (Table 1) have reached
up to 99% prediction accuracy when compared to curated
clinical typing results [67, 68]. Although many class I typ-
ing algorithms exist, OptiType [69], Polysolver [70], and
PHLAT [71] currently have the highest reported accuracies
[67, 68, 70]. Despite the high precision of class I tools, class
II HLA typing algorithms remain less reliable and require
additional development to improve their prediction accur-
acy. Few benchmarking studies that consider class II algo-
rithm accuracy have been performed, but a combined class
I and II comparison demonstrated that PHLAT [71], HLA-
VBSeq [72], and seq2HLA [73] performed well with WES
and RNA-seq data [67]. Additional HLA typing algorithms,
xHLA [74] and HLA-HD [75], have recently been pub-
lished and show comparable accuracies to those of the tools
described above.
Tumor-specific T cell recognition relies on efficient
antigen presentation by tumor cells, so one mechanism of
resistance to immunotherapies is the loss or attenuated
expression of the HLA gene loci. Recently, researchers
have identified transcriptional HLA repression in a patient
with Merkel cell carcinoma (MCC) following treatment
with autologous T cell therapy and ICB [76]. The authors
found that the transcriptional silencing can be reversed in
ex vivo cultures by treatment with 5-aza and other hypo-
methylating agents, indicating that reversing the epigen-
etic silencing of the HLA genes could sensitize tumors
that exhibit HLA downregulation in response to immuno-
therapies [77].
Genetic changes at the HLA locus can be determined by
Polysolver [70], an algorithm that detects HLA-specific
somatic mutations from computational HLA typing and
variant calling of the tumor HLA locus. Somatic mutation
analysis of head and neck squamous cell carcinoma
(HNSCC), lung cancer, and gastric adenocarcinoma co-
horts demonstrated that HLA mutations are prevalent in
all three cancer types [78–80]. In addition, HLA mutations
(particularly frameshifts, nonsense, and splicing mutations)
are enriched towards the beginning of the genes or within
functional domains, where they would be expected to result
in a loss-of-function phenotype [70]. Another tool,
LOHHLA, can identify copy number variations in the HLA
locus that result in loss of heterozygosity [81].
Additional components of the antigen presenting ma-
chinery, including B2M and TAP (Transporter associated
with antigen processing), have been shown to accrue
mutations and to exhibit altered expression patterns in tu-
mors. In lung cancer and MSI-CRC, mutations or biallelic
loss of B2M causes lack of class I HLA presentation [82,
83]. Downregulation of B2M, TAP1, and TAP2 expression
has also been shown to inhibit tumor antigen presentation
[84, 85] and correlate with metastatic breast cancer pheno-
types [86]. Identifying and characterizing altered HLA and
associated presentation genes will allow clinicians to
prioritize neoantigens that bind to expressed and unmu-
tated alleles.
Predicting peptide processing
Recognition of a peptide-MHC (pMHC) complex by the
T cell is a complex process with many steps and require-
ments. Most of the attention in the field has been focused
on predicting the binding affinity between the patient’s
MHC molecule and a given peptide sequence, as this is
believed to provide much of the specificity of the overall
recognition [87]. However, even if a peptide has strong
MHC binding prediction, the prediction may be meaning-
less if upstream processing prevents the actual loading of
that peptide. In general, pipelines generate k-mer peptides
using a sliding window that is applied to the mutant pro-
tein sequence, and these peptide sequences are subse-
quently fed into algorithms that predict the affinity of the
peptide to the corresponding MHC. However, not all of
the k-mers can be generated in vivo due to the limitations
of the immune proteasome. In addition, only a subset of
generated peptides will be transported into the appropri-
ate cellular compartments and will interact with MHC
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Table 2 Key analysis considerations and practical guidance for clinical neoantigen workflows
Analysis area Guidance
Reference genome sequences The choice of human reference genome sequences can have important implications for
various analysis steps throughout neoantigen characterization workflows. A consistent
build or assembly (e.g., GRCh38 or GRCh37) of the genome should be used throughout
the analysis. Even if two resources provide annotations that are based on the same
assembly, they may organize or name sequences differently and might follow different
conventions for representing ambiguous or repetitive sequences. They may also drop
some sequences (e.g., alternative contigs) or add sequences that are not part of the
official assembly (e.g., ‘decoy’ sequences). The use of reference files from multiple
sources for different tools is difficult to avoid but should be pursued cautiously. For
example, the naming of chromosomes and contigs used for DNA read alignment and
variant calling should be compatible (identical) to those used in transcript annotations.
Otherwise, this may prevent correct prediction of the protein sequences of neoantigens
Use of alternative contigs in the reference genome The inclusion or exclusion of alternative contigs from the latest human reference
genome build can have important implications for HLA typing tools such as xHLA [74].
In particular, if a tool assumes that all relevant reads for HLA typing can be extracted
from an existing alignment (rather than performing de novo re-alignment of all reads), it
matters whether some of these reads may have been placed on alternative contigs for
the HLA locus of chromosome 6. Some HLA typing approaches avoid this issue by
aligning all reads directly to a database of known HLA gene sequences (e.g., from the
IPD-IMGT/HLA resource). This has the disadvantage that without competitive alignment
of each read to the whole genome, some reads may be misaligned to the known HLA
sequences and this may affect accuracy during HLA typing. A reference genome
alignment approach, in which the diversity of HLA loci is properly represented in the
reference, avoids this concern and has the potential to leverage alignments that may
have already been produced for variant calling. For example, all reads aligning to the
HLA loci of chromosome 6, the corresponding alternative contigs (if present in the
reference), and unaligned reads could be extracted from a BAM file and used for HLA
typing
Transcript annotation build versions Transcript annotation resources (e.g., Ensembl, RefSeq, GENCODE, and Havana) update
their transcript sequences and associated annotations more frequently than new
reference genome sequence builds/assemblies are released. For example, Ensembl is
currently on version 96, the 21st update since the latest release of the human reference
genome, build GRCh38. As with reference genome builds, it is highly desirable to use a
consistent set of transcript annotations across the steps of a neoantigen characterization
workflow. For example, the transcripts used to annotate somatic variants should be the
same as those used to estimate transcript and gene abundance from RNA data
Variant detection sensitivity Correct neoantigen identification and prioritization rely on somatic and germline variant
detection (for proximal variant analysis) and variant expression analysis. QC analysis of
both DNA and RNA data should be performed to assess the potential for a high false-
negative rate in detecting somatic variants that might lead to neoantigens, to identify
germline variants in phase with somatic variants that influence the peptide sequence
bound by MHC, or to assess the expression of these variants. Tumor samples vary
significantly in their level of purity and genetic heterogeneity. Common strategies to
achieve high sensitivity in variant detection involve increasing the average sequencing
depth and combining results from multiple variant callers
Combining variants from multiple callers The majority of somatic variant callers now use the widely adopted variant call format
(VCF). Furthermore, many toolkits now exist for the manipulation of these files, including
merging. However, because of the complexity and flexibility of the VCF specification
(https://samtools.github.io/hts-specs/VCFv4.2.pdf), the existence of multiple versions of
the specification, and the varying interpretations of VCF rules observed in the output of
somatic variant callers, great care must be taken when combining multiple VCFs and
using these merged results. Important considerations include: (i) variant justification and
parsimony such as left aligning or trimming variants to harmonize those that can be
correctly represented at multiple positions without changing the resulting sequence
(e.g., GATK LeftAlignAndTrimVariants); (ii) normalization of multi-allelic variants by
separating multiple variant alleles that occur at a single position into multiple lines in a
VCF (e.g., vt decompose); (iii) harmonization of sequence depths, allele depth, and allele
fraction values that may be calculated inconsistently by different variant callers through
the use of an independent counting tool, such as bam-readcount (https://github.com/
genome/bam-readcount); (iv) determining the final status for each variant (PASS or
filters failed; e.g., GATK SelectVariants); and (v) choosing the variant INFO and FORMAT
fields to represent in the final merged VCF
Variant refinement (‘manual review’) Somatic variant calling pipelines remain subject to high rates of false positives,
particularly in cases of low tumor purities or of insufficient depth of sequencing of
tumor (or matched normal) samples or sub-clones. Prior to final neoantigen selection, all
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Table 2 Key analysis considerations and practical guidance for clinical neoantigen workflows (Continued)
Analysis area Guidance
somatic variants should be carefully reviewed for possible alignment artifacts, systematic
sequencing errors, nearby in-phase proximal variants, and other issues using a standard
operating procedure for variant refinement, such as that outlined by Barnell et al. [27]
Choosing RNA and DNA variant allele fraction
(VAF) cutoffs
It is impossible to define universal VAF recommendations because of the varying
distribution of VAFs observed for tumor samples with different sequencing depths,
tumor purity/cellularity, genetic heterogeneity, and degree of aneuploidy. The
interpretation of each individual candidate may be influenced by one or more of these
factors. In general, however, neoantigens corresponding to somatic variants with higher
VAFs (in both DNA and RNA) will be considered with higher priority. Estimating the
overall purity of the DNA sample by VAF distribution and distinguishing founding
clones from sub-clones requires accurate assignment of each variant to a copy number
estimate. Accepting or rejecting candidates on the basis of VAF requires a nuanced
approach that takes the characteristic of each tumor into account. For example, a variant
with a relatively low DNA VAF may be accepted in some cases if sequencing depth at
the variant position was marginal, leading to a less accurate VAF estimate. A variant with
a relatively high DNA VAF may be rejected if RNA-seq analysis shows strong evidence of
allele-specific expression (of the wild-type allele)
Interpretations that depend on RNA quality
assessment
Attempting to define expressed and unexpressed variants by RNA-seq analysis is a
common feature of many neoantigen characterization workflows. Applying hard filters
in this area should be pursued with great caution. All interpretation of RNA-seq should
be accompanied by comprehensive QC analysis of the data [204]. A lack of evidence for
expression in RNA-seq data may not be definitive evidence of non-expression of a
variant because not all genes can be robustly profiled by RNA-seq (for example, very
small genes may be poorly detected by standard RNA-seq libraries [205]). Tumor
samples that are obtained in clinical workflows, particularly those involving FFPE, may
frequently result in poor-quality RNA samples. In these cases, the requirements for
expression support may be relaxed when nominating neoantigen candidates.
Furthermore, some variants occur within a region of a gene that is difficult to align
reads to. In these cases, robust apparent expression of the gene may still be used to
nominate a neoantigen even in the absence of evidence supporting the expression of
the variant allele itself. Use of spike-in control reagents and routine profiling of reference
samples can be helpful in determining consistent expression value cutoffs (e.g., FPKM or
TPM values) across samples. In the absence of reliable gene or variant expression
readout for an individual tumor, robust expression of the gene in tumors of the same
type may be used to prioritize neoantigens
Assessing variant clonality A major consideration in the interpretation of DNA VAFs of variants is the assessment of
tumor clonality. Neoantigens corresponding to variants that reside in the founding
clone are inherently more valuable therapeutically than those residing in tumor sub-clones,
because the former have the potential to target the elimination of all tumor cells. In
personalized cancer vaccine designs, after correcting for ploidy and tumor purity, VAFs
should be interpreted to prioritize neoantigens that correspond to founding clones
Variant types and agretopicity Calculation of ‘agretopicity’ (also known as ‘differential agretopicity index’ [121], or ‘wild-
type/mutant binding affinity fold change’) refers to an attempt to estimate the degree
to which a neoantigen’s ability to bind to MHC differs from that of its corresponding
wild-type sequence. This calculation thus depends on the ability to define a wild-type
counterpart for each neoantigen sequence. For non-synonymous SNVs, the wild-type
counterpart sequence is assumed to be a peptide of the same length without the
amino acid substitution. For many other variant types, defining a counterpart wild-type
sequence is much less obvious because the variant may lead to a sequence that is
entirely novel and shares little or no homology with the wild-type sequences encoded
from the region of the variant. These include frameshift mutations caused by deletions or
insertions, translocations that lead to in-frame or frame-shifted RNA fusions, alternative
isoforms caused by aberrant RNA splicing that lead to partial or complete intron retention,
novel exon junctions, and so on. In these cases, agretopicity values are typically not calculated
and may be reported as not applicable. This should be taken into consideration when
prioritizing variants of mixed type using these values. Interpretation of agretopicity is primarily
relevant when the mutant amino acid(s) involve anchor residues of the MHC [206]
HLA naming conventions Neoantigen characterization workflows should consistently adopt the widely used
standards and definitions for the communication of histocompatibility typing information
[207]. Briefly, HLA alleles are named using an HLA prefix followed by a hyphen, gene
designation, asterix separator, and four fields of digits delimited by colons (e.g., HLA-A*02:
101:01:02 N). The four fields (typically of two or three digits each) represent the allele group,
specific HLA protein, synonymous changes in the coding region, and non-coding
differences, respectively. Several popular HLA typing bioinformatics tools only report two
field HLA types. The first two fields are generally sufficient for pMHC binding affinity
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Table 2 Key analysis considerations and practical guidance for clinical neoantigen workflows (Continued)
Analysis area Guidance
predictions because they describe any polymorphisms that influence the protein sequence
of MHC. However, three-field typing might be desirable for patient-specific assessment of
expression, because even silent variations in the DNA sequence of the HLA locus may
influence read assignments to specific alleles
HLA typing (class I vs II typing) Accurate HLA typing is critical to neoantigen characterization workflows. Without
accurate knowledge of the HLA alleles of an individual, it is not possible to predict
pMHC binding and presentation on tumor cells or cross presentation by APCs. Many
clinical- or research-grade HLA typing assays are available, and they rely on PCR
amplification or, more recently, NGS data. HLA typing results from a CAP/CLIA-regulated
assay are expected to be robust and remain the gold standard. In addition to clinical
HLA typing, there are now several bioinformatics tools and pipelines available for HLA
typing from whole genome, exome, or RNA-seq data (Table 1). Several groups have
now conducted comparisons between the results of these tools and clinical assay results
and have reported high concordance, particularly for class I typing. Class II typing
remains challenging, with fewer tools available and poorer consistency between the
results of these tools and clinical assays. Use of clinical-typing results remains advisable
for class II. As in other areas of neoantigen analysis, the use of a consensus approach
involving multiple tools has become a common strategy to increase confidence in HLA
typing results [208]
HLA typing (selection of data type and samples) Several options are available for input data when performing HLA typing from NGS data,
including DNA (WES or WGS) or RNA-seq data. RNA-seq data often exhibit highly variable
coverage across the HLA loci, potentially leading to variable accuracy in typing for each.
Coverage data from exome data may vary depending on the exome reagent’s design (probes
selected against HLA regions) and capture efficiency. Care should be taken to evaluate
sufficient read coverage for each HLA locus when assessing HLA-typing confidence. WGS data
may exhibit comprehensive breadth of coverage, but generally at the expense of overall
depth of coverage (again coverage achieved for the HLA loci specifically should be
evaluated).
In addition to data type, there is also the choice of whether to perform HLA typing using
data from the tumor itself or a reference normal sample. The normal sample has the
advantage that it should represent the germline HLA alleles present in both the initiating
cells of the tumor and the antigen presenting cells of the immune system (relevant for
cross-presentation). In many clinical and research workflows, the quality of genomic DNA
may be higher in the normal sample than in the tumor (often a FFPE-preserved sample).
The genomic DNA of the tumor may also be complicated by aneuploidy that affects the
HLA loci (which is important to observe and has the potential to interfere with HLA typing).
HLA typing using the tumor DNA data has the advantage that it may more accurately
reflect the MHC binding and presentation of neoantigens on the surface of the targeted
tumor cells. However, it is important to note that HLA-typing tools are, for the most part,
not designed for de novo HLA typing; instead, they seek to determine which of a list of
known alleles best explain the sequence reads of a given data set. HLA-typing tools also
generally do a poor job of reporting HLA-typing confidence. At present, identification of
the loss of expression or a somatic mutation of an HLA allele in a tumor is perhaps best
treated as a separate exercise from HLA typing. One strategy for choice of data for HLA
typing is to use all of the datasets available (DNA and RNA, normal and tumor), to note any
discrepancies, and to investigate them
HLA expression and mutation Loss of expression of MHC molecules by HLA deletion (or downregulation) and somatic
mutation of HLA loci have both been identified as possible resistance mechanisms for
immunotherapies [76]. It is therefore desirable for neoantigen characterization workflows to
incorporate examination of HLA expression and somatic mutation in the tumor.
Unfortunately, very few tools and best practices exist for these examinations. Given the
sequence diversity of the HLA loci across individuals, when estimating the expression of
HLA transcripts in a tumor, it is desirable to customize the reference transcripts used (e.g.,
from the IPD-IMGT/HLA resource) for each individual’s HLA type by using the results of HLA
genotyping to select the matching transcript sequences (three-field matched) for
expression abundance estimation (for example, with Kallisto)
Class I versus class II allele specification for binding
prediction algorithms
Class I HLA alleles are typically supplied to binding affinity prediction algorithms using a
standard two-field format (e.g., HLA-A*02:01). However, class II alleles are often supplied
as a pair using valid two-field pairing combinations (e.g., DQA1*01:01-DQB1*06:02) to
reflect the functional dimers of class II MHC. Peptide MHC prediction tools will typically
document the syntax and list the valid pairings for which binding-affinity predictions are
supported
Proximal variation Neoantigen selection pipelines often focus entirely on one variant or position at a time,
and consider it to be independent of all nearby variations. It is important to examine
candidates carefully to determine whether nearby variation exists that is both in phase
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Table 2 Key analysis considerations and practical guidance for clinical neoantigen workflows (Continued)
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(on the same allele) and close enough to influence the peptide sequence and therefore
the MHC binding predictions [117]
Peptide-length considerations Many human class I pMHC binding affinity prediction tools support a range of peptide
lengths for each individual HLA allele (e.g., IEDB supports lengths of 8–14 amino acids for
class I for HLA-A*01:01). Typically, although multiple lengths are supported, the peptides
that are found to have strong binding will be highly biased towards the lengths actually
favored by the allele (for example, many human HLA alleles strongly favor nonamers).
The open binding groove of MHC class II is thought to support a greater range of peptide
lengths. This is reflected in some class II binding prediction tools, although it should be
noted that the IEDB API and web resource currently enforce a length of 15 amino acids
only
Relationship between genomic variants and short
peptides
There is a complex relationship between genomic variants and the short peptide
neoantigen candidates that they might represent. Though rare, it is possible for multiple
distinct somatic variations to result in the same amino acid change (for example, several
single nucleotide substitutions affecting a single triplet codon) and therefore they might
lead to identical neoantigens. If these variations were to occur on opposite alleles, it
might be important to analyze them separately because they could differ in expression
level and/or their proximal variants, giving rise to distinct peptides. Other ways in which
a single genomic variant can give rise to distinct short peptides for pMHC binding
prediction include: (i) a homozygous somatic variant representing two distinct alleles; if
these alleles are in phase with one or more nearby heterozygous proximal variants,
distinct peptide sequences may result; (ii) SNVs expressed in different RNA transcripts or
isoforms that differ in their reading frame at the position of the variant, in the inclusion
or exclusion of nearby alternative exons, or in the nearby use of alternative RNA splicing
donor or acceptor sites; and (iii) multiple short peptides that result simply from shifting
the ‘register’ of the somatic variant in a short sequence or from the use of multiple
peptide lengths (e.g., 8–11-mers) during the prediction of pMHC binding affinity.
In some ways, mostly similar peptide sequences do not matter in peptide vaccine
design because a longer peptide will ultimately incorporate several of them into a
single peptide sequence. However, pMHC binding prediction algorithms require that
you supply a short sequence, of a specific length with the variant in a particular register,
and each of these lead to different predicted binding affinity values. Making decisions
about how to summarize, collapse, filter, and select representatives is one of the
complexities that are addressed by pipelines such as pVACtools
Importance of transcript annotation quality and
choice to select a single transcript variant
annotation
Peptides that are considered as potential neoantigens are generally derived from the
anticipated open reading frame of a known or predicted transcript sequence. A
common consideration in variant effect annotation is whether to allow annotations for
each variant against multiple transcripts or whether a single representative transcript
should be selected. If choosing a single transcript for each gene, multiple strategies
exist including the following: (i) use of a pre-selected automatically determined or
manually curated choice of ‘canonical’ transcript for each gene; or (ii) considering all
transcripts but selecting the single transcript that results in the most confident and/or
consequential predicted functional impact. The latter is the basic intent of the ‘--pick’ option
of the Ensembl Variant Effect Predictor (VEP), which chooses one block of
annotations for each variant using an ordered set of criteria (refer to the VEP documentation
for extensive details). The benefit of choosing a single transcript for the annotation of each
variant is simplicity, and in many cases, it will result in the selection of a suitable peptide
sequence for neoantigen analysis. However, the downside is that distinct peptides may not
be considered and the peptide corresponding to the selected annotation is not guaranteed
to be the best.
Note that a single variant may be assigned annotations for: multiple genes, multiple
transcripts of the same gene, and multiple effects for the same transcripts. For example,
a single variant can be annotated as splicing-relevant (near the edge of an exon causing
exon skipping) and also as missense (causing a single amino acid substitution). The
same variant could be silent for a different transcript of the same gene and have a
regulatory impact on a transcript of another gene. Making sensible automated choices
about how to choose and report neoantigen candidates that correspond to these
variants is a complexity that neoantigen characterization workflows seek to address
Importance of transcript annotation quality When using VEP, it can be important to consider the Transcript Support Level assigned
by Ensembl. As described above, this classification is one of many factors that are
considered in choosing a single ‘best’ transcript for the annotation of variants.
Occasionally, a variant annotation will be reported with a dramatic effect (e.g.,
nonsense) but on further inspection, it is found that this effect is only true for a
transcript that is poorly supported by sequence evidence, and another more reliable
transcript would lead to different candidate neoantigen sequences
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molecules. These aspects of peptide processing, specific-
ally immune proteasome processing and peptide cleavage,
must be considered and several tools have been developed
to address this component specifically [88].
For both the MHC class I and II pathways, an important
upstream step prior to pMHC interaction is proteolysis,
which refers to the degradation of proteins into peptides,
particularly by the immunoproteasome. Multiple tools are
now available to capture the specificity of proteasomes
and to predict the cleavage sites that are targeted by differ-
ent proteases. These tools include NetChop20S [89],
NetChopCterm [89], and ProteaSMM [89, 90] for MHC
class I antigens, and the more recent PepCleaveCD4 and
MHC NP II for MHC class II antigens [91, 92]. Algo-
rithms that have been developed in this area are generally
trained on two different types of data, in vitro proteasome
digestion data or in vivo MHC-I and -II ligand elution
data. The neural network-based prediction method
NetChop-3.0 Cterm has been shown to have the best per-
formance in predicting in vivo proteolysis that provides
peptide sources for MHC class I antigen presentation [88].
Cleavage site predictions for MHC class II epitopes show
promise, but have yet to be validated for predicting im-
munogenicity [88, 92].
For MHC class I antigen processing, peptide fragments
are generated from proteins that are present in the
Table 2 Key analysis considerations and practical guidance for clinical neoantigen workflows (Continued)
Analysis area Guidance
Selection of pMHC binding affinity prediction
cutoff(s)
Many pMHC binding prediction tools report binding strength as an IC50 value in
nanomolar (nM) units. Peptides that have a binding affinity of less than 500 nM are
commonly selected as putative strong binding peptides. However, the widespread use
of this common binding strength metric may provide a false sense of consistency.
Trusting a simple cutoff of 500 nM from a single algorithm should be avoided, but
combining scores from multiple algorithms should also be pursued very cautiously. The
range, median, and even shape of distribution of IC50 scores varies dramatically across
algorithms, even when applied to exactly the same peptides [8]. Further complicating
the selection process, the accuracy of the IC50 estimates varies across HLA alleles
(reflecting the biased and variable strength of experimental evidence used to train
generalized predictive models). Partially addressing this concern, the IEDB now provides
recommended ‘per allele’ binding-score thresholds for the selection of strong binders
Interpretation of binding affinity from multiple
binding prediction algorithms
Given the variability in IC50 predictions across binding prediction algorithms, some
neoantigen workflows involve the use of multiple binding prediction tools and attempt
to calculate or infer a consensus. Best practices for determining such a consensus are
poorly articulated, and limited gold-standard independent validation data sets exist to
evaluate the accuracy of divergent predictions. Unsophisticated but pragmatic
approaches currently involve reporting the best score observed, calculating the median
score, determining average rank values, or manually visualizing the range of predictions
across algorithms for promising candidates, before making a qualitative assessment
Neoantigen candidate reporting, visualization, and
final prioritization
Prior to the final review of candidates, the automated filtering of variants and peptides
that do not meet basic criteria (VAFs, binding affinity, and so on) is performed to
provide a more interpretable result. As discussed above, a single genomic variant can
lead to many candidate peptide sequences (resulting from alternative reading frames,
peptide lengths, registers, and so on). At the time of final candidate review and
selection, a common strategy is to use a pipeline that will automatically choose a single
representative (best) peptide for each variant in a filtered result. Similarly, a condensed
report may be generated to present only the most important information about each
candidate. Final assessment of a candidate neoantigen can easily involve the
consideration of 20–50 specific data fields. Review of this data in spreadsheet form can
be time-consuming and inefficient, and can make it difficult to consider some data in
the context of a cohort of comparators (for example, expression values are often best
interpreted relative to reference samples). Tools such as pVACviz are now emerging to
facilitate more efficient visual interfaces for neoantigen candidate review
Vaccine manufacturing strategy In the case of personalized cancer vaccine trials, the method of vaccine delivery can
influence bioinformatics tool selection and other analysis considerations. For example, if
candidates are to be encoded in a DNA vector, a tool such as pVACvector may be used
to determine the optimal ordering of the peptide candidates. Owing to the
combinatorial nature of candidate peptide sequence ordering, and the need to examine
all pairs for junctional epitopes, this is currently one of the most computationally
expensive and time-consuming steps of these workflows. Similarly, if peptides are to be
synthesized for a peptide vaccine, there is a need to predict possible problems with
synthesizing each peptide (for example, by calculating ‘manufacturability’ scores)
A detailed summary of analysis and interpretation best practices and nuances that should be considered when implementing a neoantigen identification
workflow. Topics are covered in an order that corresponds to the flow of major steps discussed in the main body and depicted in Fig. 1. For further nuanced
details on how to put the following guidance into practice, please refer to our tutorial on precision medicine bioinformatics (https://pmbio.org/). Abbreviations:
CAP College of American Pathologists, CLIA The Clinical Laboratory Improvement Amendments, FPKM fragments per kilobase of exon model per million reads
mapped, TPM transcripts per million
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cytoplasm and transported by the TAP protein into the
endoplasmic reticulum (ER), where the peptide is loaded
onto an MHC molecule. Thus, in addition to tools fo-
cusing on the process of proteolysis, other tools have
also been developed to predict the efficiency of peptide
transportation on the basis of affinity to TAP proteins.
Different methods have been employed in an attempt to
determine which peptides have high affinity for TAP bind-
ing, including simple/cascade support vector machine
(SVM) models [93, 94] and weight matrix models [95]. To
address the entirety of this process, the Immune Epitope
Database (IEDB) has also developed a predictor for the
combination of these processes (proteasomal cleavage/
TAP transport/MHC class I) [90, 96].
In the MHC class II pathway, the peptides are mostly
exogenous and enter the endosome of APCs through
endocytosis. As endosomes mature into late endosomal
compartments, acidity levels increase and serine, aspar-
tic, and cysteine proteases are activated. Proteins, upon
exposure to a series of proteases, are degraded into po-
tential antigens for presentation. MHC class II molecules
are assembled in the ER and transported to these high
acidity late endosomes, also known as MHC-II compart-
ments (MIIC). Here, peptides can bind to class II mole-
cules and are protected from destructive processing [97,
98]. In contrast to the protein denaturation in the MHC
class I processing pathway, cleavage in the MHC class II
pathway occurs on folded proteins. Predictors for class
II peptide preprocessing prior to MHC binding show the
important role that secondary structures play in such re-
actions, as multiple measures related to secondary struc-
tures were found to be highly correlated with the
predicted cleavage score [91]. Consideration of secondary
structure will be critical to the future development of tools
predicting class II processed peptides. However, although
the class I antigen processing pathway has been studied
extensively, researchers have only recently started to focus
on class-II-specific neoantigens as promising results have
been shown in cancer immunotherapies [99–101]. There
remains a great need to develop supporting tools and al-
gorithms to characterize class-II-specific neoantigens.
For the purposes of neoantigen prioritization, it is im-
portant to take into account processing steps such as pep-
tide cleavage and TAP transport when using binding
prediction algorithms that were trained on in vitro binding
data. Recently, published binding prediction algorithms
have been transitioning to training on data generated
in vivo, in which case the processing steps are accounted
for intrinsically.
MHC binding prediction
Neoantigen characterization pipelines have been estab-
lished specifically to predict the binding of neoantigens
to the patient’s specific class I and II MHC molecules
(based on HLA typing). Algorithmic development and
the refinement of reference data sets are very active in
this area. Here, we describe the current state of the art
with respect to algorithmic innovation and refinement of
the major classes of data that are used to train these al-
gorithms (largely from in vitro binding assays involving
specific MHCs and peptide libraries or from MS-based
approaches) [87, 102–104].
Peptides bind MHC molecules at a membrane-distal
groove that is formed by two antiparallel α-helices overlay-
ing an eight-strand β-sheet [97]. The peptide-binding re-
gion of the MHC protein is encoded by exons 2 and 3 of
the corresponding HLA gene [105]. High allelic polymorph-
ism allows the binding pocket of MHC molecules to
recognize a range of different peptides sequences, and the
positions that are involved in anchoring the peptide to the
MHC molecule in particular vary for each HLA allele. The
algorithms and training datasets for predicting pMHC
binding remain an active area of development. Various
methods have been employed in an attempt to capture the
characteristics of peptide and MHC molecules that have a
high probability of binding (Table 1).
Early algorithms have mostly focused on training using
in vitro pMHC binding affinity measurement datasets.
MHC peptide binding is thought to be the most selective
step in the antigen presentation process, but sole consid-
eration of peptide binding predictions still results in high
rates of false-positive predictions of neoantigens for appli-
cations in personalized immunotherapy [28, 29]. This in-
sufficiency probably results from the influence of other
factors including the preprocessing of peptides, the stability
of the pMHC complex [106, 107], and peptide immuno-
genicity [108]. Recently published MHC binding algorithms
use either only peptidome data, generated from in vivo im-
munoprecipitation of pMHC complexes followed by MS
characterization, or an integration of MS and binding-
affinity data [87, 102, 104]. By directly examining ligands
that are eluted from pMHC complexes identified in vivo,
predictive models can capture features unique to peptides
that have undergone the entire processing pathway. Over
150 HLA alleles have corresponding binding-affinity datasets
available in IEDB (with highly variable amounts of data for
each allele) [96]. By contrast, MS peptidome datasets are
available for only approximately 55 HLA alleles [87], prob-
ably because of the lack of high-throughput characterization
assays. However, continuous development in MS profiling
techniques [109] may soon close the gap between the two
types of data. Zhao and Sher [110] recently performed sys-
tematic benchmarking for 12 of the most popular pMHC
class I binding predictors, with NetMHCpan4 and
MHCflurry determined to have the highest accuracy in
binding versus non-binding classifications. The analysis also
revealed that the incorporation of peptide elution data from
MS experiments has indeed improved the accuracy of recent
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predictors when evaluated using high-quality naturally pre-
sented peptides [110].
Different types of algorithmic approaches have been
used to model and make predictions for the binding affin-
ity of MHC class I molecules. Initially, predictors relied on
linear regression algorithms and more specifically on sta-
bilized matrix methods, such as SMM [111],
SMMPMBEC [112], and Pickpocket [113]. However, re-
cently published or updated predictors almost exclusively
employ variations of neural networks [87, 102, 104, 114],
as shown in Table 3. Linear regression assumes a linear
contribution of individual residues to the overall binding
affinity; however, while artificial neural networks require
more training data, they are able to capture the nonlinear
relationship between the peptide sequence and the bind-
ing affinity for the corresponding MHC molecules
through hidden layers in their network architecture. Given
the growing number of available training datasets, applica-
tions of artificial neural networks have been able to
achieve higher accuracy than that provided by linear re-
gression predictive methods [110].
While prediction algorithms for MHC class I molecules
are well developed, algorithms for MHC class II are fewer,
less recently developed, and trained with smaller datasets.
Unlike MHC class I molecules, class II molecules are
heterodimeric glycoproteins that include an ɑ-chain and a
β-chain; thus, MHC II molecules are more variable than
MHC I molecules as a result of the dimerization of highly
polymorphic alpha and beta chains. The binding pocket
for class II molecules is open on both ends, which allows a
larger range of peptides to bind. The most frequently ob-
served lengths of peptides that bind to class II MHCs are
between 13 and 25 amino acids [115], whereas those for
class I typically fall between 8 and 15 amino acids [87].
Nevertheless, for any one particular MHC allele, the pre-
ferred number of amino acids may be much more con-
strained to one or two lengths. Algorithms built for class
II predictions generally rely on matrix-based methods and
ensembles of artificial networks. A selection of popular
MHC class II binding prediction algorithms are summa-
rized in Table 1 [116].
There is an extensive list of MHC binding prediction
tools for both class I and class II molecules, but there re-
mains a need not only to expand the training data for a lar-
ger range of HLA alleles but also to refine the type of
training data being used in these algorithms. Although
in vivo MS data capture the features of peptides that are
naturally presented by MHC molecules, they cannot con-
firm whether such peptides are able to induce an immune
response. Algorithms should ideally incorporate experimen-
tally and clinically validated immunogenic peptides in their
training and validation datasets. As ongoing neoantigen
clinical trials produce more of such data, tool development
and refinement in this area will also become possible.
Neoantigen prioritization and vaccine design
pipelines
Owing to the numerous factors that are involved in the
process of antigen generation, processing, binding, and rec-
ognition, a number of bioinformatic pipelines have emerged
with the goal of assembling the available tools in order to
streamline the neoantigen identification process for differ-
ent clinical purposes (such as predicting the response to
ICB, designing peptide- or vector-based vaccines, and so
on). Table 1 includes a selection of these pipelines and
Table 2 provides extensive practical guidance for their use
in clinical studies. These pipelines address multiple factors
that should be given careful consideration when attempting
to predict neoantigens for effective cancer treatments.
These considerations include: the use of multiple binding
prediction algorithms (variability among binding predic-
tions); the integration of both DNA and RNA data (expres-
sion of neoantigen candidate genes or transcripts and
expression of variant alleles); the phasing of variants (prox-
imal variants detected on the same allele will influence
neoantigen sequences) [32, 117]; the interpretation of vari-
ants in the context of clonality or heterogeneity [118]; the
HLA expression and somatic mutations of patient tumors;
and the prediction of tumor immunogenicity [119, 120].
These pipelines are able to provide a comprehensive sum-
mary of critical information for each neoantigen prediction,
including: variant identity (genomic coordinates, ClinGen
allele registry ID, and Human Genome Variation Society
(HGVS) variant name); predicted consequence of the vari-
ant on the amino acid sequence; corresponding gene and
transcript identifiers; peptide sequence; position of the vari-
ant within the candidate neoantigen peptide; binding affin-
ity predictions for mutant peptides and the corresponding
wild-type peptide sequences; agretopicity value (mutant
versus wild-type peptide binding affinity) [121]; DNA vari-
ant allele frequency (VAF); RNA VAF; and gene expression
values for the gene harboring the variant. Additional data
on whether peptides are generated from oncogenic genes,
peptide stability, peptide processing and cleavage, and pep-
tide manufacturability should also be considered for final
assessment of neoantigens (Table 2).
Several pipelines attempt to integrate DNA and RNA
sequencing data by evaluating the VAFs and the gene or
transcript expression values of the mutations. Most pipe-
lines currently take into account SNVs and indels, with
only a subset considering gene fusion events [8, 32, 122].
Consistent use of the same build or assembly of the gen-
ome throughout analysis pipelines, as well as an emphasis
on quality control (QC) when performing variant detec-
tion and expression analysis, is important for ensuring
high confidence in the variants that are detected (Table 2).
Once the mutations are confirmed to exist and be
expressed, the pipelines then generate a list of neoantigen
candidates and consider the probability of cleavage, the
Richters et al. Genome Medicine           (2019) 11:56 Page 12 of 21
location of cleavage, and the TAP transport efficiency
of each candidate [8, 123, 124]. The binding affinities of
the peptides to the patient-specific MHC molecules are
subsequently predicted by using one or more algo-
rithms (Table 1). However, binding-affinity predictions
that are made by multiple prediction algorithms vary,
and best practices for determining a consensus are
poorly articulated at this time. Furthermore, the gold-
standard independent validation datasets that exist to
evaluate the accuracy of divergent predictions are lim-
ited. It remains to be determined whether combining
multiple prediction algorithms increases the true posi-
tive rate of neoantigen predictions. Some pipelines also
consider: (i) manufacturability by measuring peptide
characteristics [9]; (ii) immunogenicity by comparing
either self-antigens defined by the reference or by the
wild-type proteome or known epitopes from viruses
and bacteria provided by IEDB [119]; and (iii) pMHC
stability [8, 107].
Pipelines vary in their choices of how to rank neoanti-
gens and which specific type of algorithm to use when
performing such calculations. Thus, a major challenge
lies in how each component should be weighted to cre-
ate an overall ranking of neoantigens in terms of their
potential effectiveness. Kim et al. [125] have attempted
to capture the contributions of nine immunogenicity fea-
tures through the training of machine-learning-based
classifiers. Nevertheless, high-quality and experimentally
validated neoantigens for training such models remain ex-
tremely sparse. In other words, there is no consensus on
the features of a ‘good’ neoantigen that would be capable
of inducing T cell responses in patients. Furthermore,
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clinicians may need to consider customized filtering and
ranking criteria for individual patient cases, tumor types,
or clinical trial designs, details that are not well supported
by the existing pipelines. For these reasons, clinical trial ef-
forts should establish an interdisciplinary team of experts
analogous to a molecular tumor board for formal quanti-
tative and qualitative review of each patient’s neoantigens.
Pipelines such as pVACtools and Vaxrank are designed to
support such groups, but there are many important areas
in current pipelines that could be improved upon, includ-
ing: i) consideration of whether the mutation is located
within anchor residues for each HLA allele; ii) somatic
mutation and expression of patient-specific HLA alleles;
iii) the expression level of important cofactors such as
genes that are involved in processing, binding, and presen-
tation; and iv) additional factors that influence the manu-
facturing and delivery of the predicted neoantigens.
Peptide creation, delivery mechanisms, and
related analysis considerations for vaccine design
Once neoantigen prioritization is complete, personalized
vaccines are designed from predicted immunogenic candi-
date sequences. Multiple delivery mechanisms exist for use
in clinical trials; these include synthetic peptides, DNA,
mRNA, viral vectors, and ex-vivo-loaded dendritic cell vac-
cines [126, 127]. Cancer vaccine delivery is an extensive
topic beyond the scope of this review, but other reviews dis-
cuss this topic in detail [126–128]. Once a mechanism is
chosen and the vaccine is delivered to the patient, profes-
sional APCs endocytose the neoantigen sequences. Then,
they are processed to generate class-I- and II-restricted
MHC peptides for presentation and T cell activation. To
design a successful delivery vector, additional analysis steps
are necessary to assess peptide manufacturability and to
avoid potential incidental DNA vector junctional epitope
sequences, or junctions spanning neoantigen sequences
that create unintended immunogenic epitopes [8, 129].
Synthetic long peptides (SLPs) are an effective neoantigen
delivery mechanism in personalized immunotherapy pre-
clinical studies and clinical trials [30, 101, 130, 131]. These
peptides are created from sequences of 15–30 amino acids
that contain a core predicted neoantigen. SLPs have greater
efficacy than short synthetic peptides, of 8–11 amino acids,
because longer peptides require internalization and pro-
cessing by professional APCs, whereas short peptides can
induce immunological tolerance by binding directly to
MHC-I on non-professional APCs [132–134]. One limita-
tion of SLPs is manufacturability. Certain chemical proper-
ties of the amino acid sequence can make peptides difficult
to synthesize, and longer peptides can encounter solubility
problems (i.e., they become insoluble). Vaxrank [9] aims to
address these concerns by incorporating a manufacturabil-
ity prediction step in the neoantigen prioritization pipeline.
This step measures nine properties that contribute to
manufacturing difficulty, including the presence of hydro-
phobic sequences, cysteine residues, and asparagine-proline
bonds. The algorithm then uses this information to choose
an ideal window surrounding the somatic mutation for
optimum synthesis.
DNA vectors have also delivered neoantigens successfully
in a recent preclinical study [135], and DNA neoantigen
vaccine clinical trials are currently ongoing in pancreatic
and triple-negative breast cancer [136]. Neoantigen encod-
ing DNA sequences can be either directly injected via plas-
mid vectors using electroporation or incorporated into viral
vectors for delivery into patient cells. Adenovirus and vac-
cinia are the most common viral vectors for personalized
vaccines; both are double-stranded DNA (dsDNA) viruses
that can incorporate foreign DNA [137]. To maximize
neoantigen effectiveness for both vectors, researchers must
design sequences with effective junctions and/or spacers.
This ensures correct cleavage of the combined sequence by
the proteasome as well as the avoidance of inadvertent im-
munogenic junction antigens. Multiple methods exist to ad-
dress these challenges.
Furin is a peptidase in the trans-Golgi network that
cleaves immature proteins at sequence-specific motifs [138].
Recently, furin-sensitive cleavage sequences were incorpo-
rated into a neoantigen DNA vaccine to cleave the sequence
into functional neoantigens [135]. EpiToolKit [123] ad-
dresses incorrect peptide cleavage in its pipeline by incorp-
orating NetChop [89]. This tool predicts the proteasomal
cleavage sites for each neoantigen and can be used to ex-
clude candidates that would undergo inappropriate cleavage.
pVACvector, an algorithm included in pVACtools [8], opti-
mizes neoantigen sequence order by running pVACseq on
the junction sequences and prioritizing those with low im-
munogenicity. If high junction immunogenicity cannot be
avoided, spacer sequences are included to decrease the po-
tential for inadvertent neoantigens. Taking such analytical
considerations into account during personalized vaccine de-
sign ensures maximum treatment efficacy in patients.
T cell recognition, TCR profiling, and immune cell
profiling to evaluate response
The ultimate objective of introducing a neoantigen-
derived vaccine is to elicit and/or expand a tumor-specific
T cell response. This can be evaluated by experimental
methods that measure T cell activation and activity, or by
computational methods that characterize the patient’s
TCR repertoire prior to and after immunotherapy. Stand-
ard methods such as IFN-γ ELISPOT assays [139] or
MHC multimer assays [140] are beyond the scope of this
review, but have been used widely for neoantigen valid-
ation purposes [28, 141]. T cells individually undergo
complex combinatorial rearrangements in the T cell re-
ceptor gene loci in order to create unique clonotypes that
are responsible for recognizing antigens. This process
Richters et al. Genome Medicine           (2019) 11:56 Page 14 of 21
occurs within the V(D) J region of the gene, particularly
the complementarity-determining region 3 (CDR3), which
encodes a region of the TCR that is important for recog-
nizing the pMHC complex. Thus, attempts to characterize
the TCR repertoire focus on the identification and
characterization of CDR3 sequences, which are represen-
tative of the unique T cell clones. This process, termed
TCR clonotyping, has been used to identify clonal T cell
responses to neoantigens following vaccination with a per-
sonalized cancer vaccine or after checkpoint blockade
therapy [28]. Researchers have also established an associ-
ation between the size and diversity of a patient’s TCR rep-
ertoire and their response to cancer immunotherapies
[142]. Changes in the clonality and diversity of the TCR
repertoire, observed from either peripheral blood or tumor-
infiltrating lymphocytes (TIL), suggest that an antitumor T
cell response is occurring, but they are global metrics that
do not successfully identify the T cell clonotypes respon-
sible for tumor rejection.
A variety of available technologies and tools allow se-
quencing and subsequent analysis of the TCR repertoire.
Commercial services such as Adaptive, ClonTech, and
iRepertoire differ in a number of aspects, including the re-
quired starting material, their library preparation methods,
the targeted TCR chains and/or CDR regions for sequen-
cing, the supported organisms, and the sequencing plat-
forms used [143]. Several tools exist to identify TCR
CDR3 sequences using various types of data, such as out-
put data from focused assays (e.g., Adaptive, ClonTech or
CapTCR), bulk tumor RNA-seq [144], and single cell
RNA-seq [144, 145], particularly from the TCR alpha and
beta genes (TRA, TRB). Challenges associated with TCR
profiling include the diversity of the repertoire itself,
correctly determining the pairing of TRA and TRB clono-
types, and the subsequent analysis or validation necessary
to pair T cell clones with their target neoantigens. Studies
have quantified or predicted the T cell richness, or total
number of T cell clones, in the peripheral blood of a
healthy individual as up to 1019 cells [146]. Thus, there is a
sampling bias—based upon the blood draw that was taken,
the sample used for sequencing, and the input material for
library preparation—that prevents complete evaluation of
the global T cell repertoire.
TCR profiling requires the alignment of sequencing
reads to the reference TCR genes and the assembly of the
rearranged clonotypes. MixCR has been used for TCR
alignment and assembly in both bulk and single-cell
methods [144, 147]. MIGEC [148] is utilized for methods
involving the use of unique molecular identifiers, whereas
TraCeR is designed specifically for single-cell methods
[145]. MiXCR recovers TCR sequences from raw data
through alignment and subsequent clustering, which al-
lows the grouping of identical sequences into clonotypes.
If sequences are generated from bulk material (e.g., whole
blood or bulk TIL), TRA and TRB sequences cannot be
paired to define the T cell clonotypes specifically. They
may be inferred on the basis of frequency, but due to the
very high diversity of the T cell repertoire, there are often
many clonotypes at similar or low frequencies that make
deconvolution of TRA–TRB pairs difficult. With the
advent of single-cell sequencing data, tools such as
TraCeR are now able to identify paired alpha–beta se-
quences within individual cells that have the same recep-
tor sequences and thus have been derived from the same
clonally expanded cells [145].
The identification of clonally expanded neoantigen-
specific TCRs complements neoantigen prediction and
characterization by indicating whether an active T cell re-
sponse has been stimulated by an immunotherapeutic inter-
vention. Lu et al. [149] recently developed a single cell
RNA-seq approach that identifies neoantigen-specific TCRs
by culturing TILs with tandem minigene (TMG)-transfected
or peptide-pulsed autologous APCs. Experimental validation
data for individual neoantigens can then be utilized to train
and improve current neoantigen prioritization strategies.
The clonality of the TCR repertoire can be further eval-
uated to identify T cell clones that may recognize the
same neoantigen. Studies have identified oligoclonal T cell
populations that converge, with consistent CDR3 motif se-
quences, to recognize the same neoantigen [150]. Taking
into account the diversity of the repertoire, these findings
suggest that oligoclonal events are more likely than mono-
clonal events, and that there is not likely to be one-to-one
mapping between T cell clones and neoantigens. Oligoclo-
nal events and the convergence of the T cell repertoire
can be better studied with tools such as GLIPH, which
was developed to identify consistent CDR3 motifs across
[151] T cells in bulk TCR sequencing.
Antitumor T cell responses have been correlated with
changes in the infiltrating immune microenvironment.
Methods such as CIBERSORT have been developed to
characterize cell compositions on the basis of gene ex-
pression profiles from tumor samples [152]. Association
between immune cell infiltrates and various factors, in-
cluding somatic mutation, copy number variation, and
gene expression, can be explored interactively through
TIMER [153]. This topic has been reviewed in more
depth elsewhere [154]. A larger selection of available
tools related to T cell and immune cell profiling are
listed in Table 1. Overall, few studies have focused on
the integration of T cell profiling with neoantigen detec-
tion, with the exception of that reported in Li et al.
[155], in which TCR clones that were identified from
RNAseq samples across Cancer Genome Atlas samples
were compared to the mutational profiles of tumors,
successfully identifying several public neoantigens that
are shared across individuals. Owing to the limited avail-
ability of peripheral blood samples and TCR sequencing
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data with matched tumor DNA or RNA sequencing, one
major area for development in the field remains the aggre-
gation of these data and the introduction of an appropriate
supervised approach to identify TCR–neoantigen pairs.
Such progress would leverage the available data to enhance
the identification of neoantigens and to optimize personal-
ized medicine approaches for cancer immunotherapy.
Conclusions and future directions
Great strides have been made in developing pipelines for
neoantigen identification, but there is significant room for
improvement. Tools for the rational integration of the
myriad complex factors described above are needed. In
some cases, useful tools exist but have not been incorpo-
rated into analysis workflows. In other cases, factors we
believe are important are not being considered because of
a lack of tools.
Variant types beyond SNVs and indels have been con-
firmed as neoantigen sources, but there remains little sup-
port for them in current pipelines. Fusions have recently
been incorporated into pipelines such as pVACfuse (a tool
within pVACtools [8]), INTEGRATE-neo [32], and Neoe-
pitopePred [122]. However, additional genomic variant
types that lead to alternative isoforms and to the expres-
sion of normally non-coding genomic regions remain un-
supported, despite preliminary analyses suggesting their
importance. An additional orthogonal, but poorly sup-
ported, neoantigen source is the proteasome, which was
found to be capable of creating novel antigens by splicing
peptides from diverse proteins to create a single antigen
[156]. Several computational tools exist to predict post-
translational modifications and alternative translation events
from sequencing data, such as GPS [157] and KinasePhos
[158] for phosphorylation events and altORFev [159] for al-
ternative ORFs. To determine the immunogenicity of these
alternative peptides, any tumor-specific predicted sequences
could be input into neoantigen prediction software.
The low accuracy of class II HLA typing algorithms
has impeded extensive class II neoantigen prediction.
When clinical class II HLA typing data are available,
they should be used in place of computational HLA pre-
dictions in pipelines to improve prediction reliability. In
addition, although somatic alterations in HLA gene loci
and in the antigen presentation machinery have been
implicated in immunotherapeutic resistance, these prop-
erties have not been leveraged in predicting neoantigen
candidates. HLA gene expression is more often summa-
rized at the gene rather than the allele level. Further-
more, HLA expression is commonly determined from
bulk tumor RNAseq data, which are derived from nor-
mal, stromal, and infiltrating immune cells, all of which
may express HLA genes. The relationship between the
present HLA alleles and a predicted neoantigen profile
has not been studied, and it remains to be seen whether
neoantigens that are restricted to absent or mutant HLA
alleles should be specifically filtered out.
For the neoantigen prediction step, mutation positions in
the neoantigen should be carefully considered if they occur
in anchor residues, since the core sequence of these pep-
tides would be unaffected and identical to that of the wild-
type protein. There is also a bias towards class I neoantigen
prediction because there are fewer binding-affinity training
data and fewer algorithms for class II neoantigens because
of their increased MHC binding complexity. Studies have
also shown low consensus across MHC binding predictors
[8]. pVACtools [8] addresses this challenge by running
multiple algorithms simultaneously and reporting the low-
est or median score, but a more definitive method for
obtaining a binding-affinity consensus remains to be devel-
oped. Neoantigen prediction pipelines could also benefit
from the inclusion of information on the proposed delivery
mechanism to improve prioritization and to streamline vac-
cine creation.
Although TCR sequences have been recognized to be
highly polymorphic, TCRs from T cells that recognize
the same pMHC epitope may share conserved sequence
features. Researchers have started to quantify these pre-
dictive features with the hope of modeling epitope–TCR
specificity [160]. Multiple tools (such as TCRex,
NetTCR, Repitope) now attempt to predict epitope–
TCR binding when given specific TCR sequences. By
taking into account the binding specificity of the pa-
tient’s existing TCR sequences, neoantigen candidates
can be further prioritized according to their immuno-
genicity. A major advance in optimizing treatment strat-
egies may require the integration of pipelines that perform
all of the steps necessary for the generation and processing
of neoantigens and for the identification of T cell clones
that efficiently recognize them.
Implementing a set of best practices to predict high-
quality immunogenic neoantigens can lead to improved
personalized patient care in the clinic. Predicting and
prioritizing neoantigens is, however, a complicated
process that involves many computational steps, each
with individualized, adjustable parameters (we provide a
specific end-to-end workflow based on our current prac-
tices at https://pmbio.org/). Given this complexity, the
review of candidates by an immunogenomics tumor
board with diverse expertise is highly recommended. We
have outlined each step in the neoantigen workflow with
human clinical trials in mind, but further research is
needed in model organisms to facilitate the development
of immunotherapies for human use. Improving neoanti-
gen characterization tools to support the in silico model-
ing of immune response, model organism systems,
human derived samples, and human patient trials is an
essential step for improving patient response rates across
cancer types.
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